Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-02-03 Carbamazepine
| Carbamazepine |
|
Formulary
|
Tablets 100mg, 200mg, 400mg Liquid 100mg/5mL Prophylaxis of bipolar disorder unresponsive to lithium. |
 MHRA: Antiepileptics: risk of suicidal thoughts and behaviour MHRA: Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions |
|
Links
LMMG SCG Lithium July 2019- LMMG SCG Lithium July2019
- LSCMMG: Lithium shared care guideline
- LSCMMG: Lithium shared care guideline
- LSCMMG: Lithium shared care guideline
- LSCMMG: Lithium shared care guideline
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- MHRA Drug SAfety Update April 2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety Update April 2019: Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme
- MHRA Drug Safety Update April2018: Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met
- MHRA Drug Safety update Feb 2016 : Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update Feb 2016: Valproate and of risk of abnormal pregnancy outcomes: new communication materials
- MHRA Drug Safety Update Sept 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA Drug Safety Update Sept 2018: Valproate Pregnancy Prevention Programme: actions required now from GPs, specialists, and dispensers
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptic drugs: updated advice on switching between different manufacturers products
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
- MHRA: Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions
- MHRA: Full pack dispensing of valproate-containing medicines
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- MHRA: Valproate use in men: as a precaution, men and their partners should use effective contraception
- NICE CG103: Delirium: prevention, diagnosis and management
- NICE CG155: Psychosis and schizophrenia in children and young people: recognition and management
- NICE CG178 Psychosis and schizophrenia in adults: prevention and management
- NICE CG185 Bipolar disorder: assessment and managemen
- NICE CG185: Bipolar disorder: assessment and management
- NICE CG192: Antenatal and postnatal mental health: clinical management and service guidance
- UHMB Lithium therapy risk assessment form
- UHMB Lithium therapy risk assessment form
- UHMB lithium therpay risk assessment form